MedTrace Logo

Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)

NCT00079482 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2016-07-21

No results posted yet for this study

Summary

The purpose of the study is to determine whether CEP-701 given in sequence with induction chemotherapy increases the proportion of patients with relapsed acute myeloid leukemia (AML) who achieve a second complete remission (CR).

Conditions

Interventions

DRUG

CEP-701

DRUG

high-dose cytarabine

Chemotherapy

DRUG

Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)

Chemotherapy

Sponsors & Collaborators

  • Cephalon

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2009-03-31
Completion
2010-01-31

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Israel
  • Italy
  • New Zealand
  • Poland
  • Romania
  • Russia
  • Spain
  • Sweden
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00079482 on ClinicalTrials.gov